Skip to Content

Diphtheria toxoid / hepatitis b pediatric vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid Disease Interactions

There are 5 disease interactions with diphtheria toxoid / hepatitis b pediatric vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid:

Major

Vaccination (Includes Diphtheria toxoid/hepatitis b pediatric vaccine/pertussis, acellular/poliovirus vaccine, inactivated/tetanus toxoid) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Fever, Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
View all 15 references
Major

Vaccines (Includes Diphtheria toxoid/hepatitis b pediatric vaccine/pertussis, acellular/poliovirus vaccine, inactivated/tetanus toxoid) ↔ Im Injection

Severe Potential Hazard, High plausibility

Applies to: Thrombocytopenia, Coagulation Defect, Thrombocytopathy, Thrombocytopathy, Thrombocytopenia, Coagulation Defect, Coagulation Defect, Thrombocytopenia, Thrombocytopathy

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 5 references
Moderate

Hepatitis B Vaccine (Includes Diphtheria toxoid/hepatitis b pediatric vaccine/pertussis, acellular/poliovirus vaccine, inactivated/tetanus toxoid) ↔ Hemophilia

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding Associated with Coagulation Defect

Hepatitis B vaccine (adult and pediatric) is usually for intramuscular administration. However, it may be administered subcutaneously to persons at risk for hemorrhage following intramuscular injections (e.g., hemophiliacs), although it may result in lower antibody response. Additionally, when other aluminum- absorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, consider subcutaneous administration only in persons who are at risk of hemorrhage following intramuscular injections.

Moderate

Hepatitis B Vaccine (Includes Diphtheria toxoid/hepatitis b pediatric vaccine/pertussis, acellular/poliovirus vaccine, inactivated/tetanus toxoid) ↔ Low Birth Weight

Moderate Potential Hazard, Moderate plausibility

Applies to: Prematurity/Underweight in Infancy

Hepatitis B vaccine should be deferred for infants with a birth weight less than 2,000 grams if the mother is documented to be HBsAg negative at the time of the infant's birth. If the mother is HBsAg positive (or the status cannot be determined), the infant should receive the vaccine within 12 hours after birth.
Apnea following intramuscular vaccination has been observed in some infants born prematurely and the decision to administer any intramuscular vaccine, including hepatitis B vaccine, should be based on consideration of the infant's medical status, and the potential benefits and risks of vaccination. Close monitoring is recommended.

Moderate

Vaccines (Inactivated)/Toxoids (Includes Diphtheria toxoid/hepatitis b pediatric vaccine/pertussis, acellular/poliovirus vaccine, inactivated/tetanus toxoid) ↔ Immunodeficiency

Moderate Potential Hazard, High plausibility

Applies to: Immunodeficiency, Immunodeficiency, Immunodeficiency, Immunodeficiency

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

References

  1. "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.
  2. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
View all 10 references

diphtheria toxoid / hepatitis b pediatric vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid drug Interactions

There are 182 drug interactions with diphtheria toxoid / hepatitis b pediatric vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide